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protective effect on Kaplan–Meier survival analysis, this disappeared when the
signiﬁcant baseline disparities seen in these patients were accounted for.
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Background: Drug-eluting stents (DES) have been related to a certain risk of late
thrombosis. The recommended duration of dual antiplatelet therapy (DAPT) with DES
is 12 months. DAPT is not free from complications and is expensive. Trials with
limited size suggest that a 6 month DAPT period could be enough with new gener-
ation DES. There are no prospective clinical registries assessing the safety of such
approach.
Methods: All consecutive patients treated with a new generation DES (Xience V,
Xience Prime, Endeavor Resolute, Promus Element, Biomatrix, Nobori, Osiro) were
prospectively included in 20 different centers. Patients had to fulﬁll one of the
following inclusion criteria in order to have 6 month DAPT period prescribed: silent
ischemia, stable angina, low risk non-ST segment elevation myocardial infarction or
acute coronary syndrome where 12 months DAPT was discarded due to high bleeding
risk. Taking advantage of the ESTROFA-2 database (4,768 patients treated with new
generation DES, 4355 of them with 12 months DAPT) we will perform a propensity
score matching of the six months DAPT from the ESTROFA-DAPT registry with the
12 months DAPT from the ESTROFA-2 registry.
Results: A total of 800 patients have been included so far in 20 centers. The baseline
characteristics of the matched groups and the 1 year follow up results of the ﬁrst 500
patients would be presented at the meeting sessions.
Conclusions: The ESTROFA-DAPT registry will provide data regarding safety of a 6
month DAPT period after new generation DES implantation.
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Background: Prolonged dual anti-platelet therapy (DAPT) is recommended after an
acute coronary syndrome (ACS) to reduce ischemic events, but is associated with
increased rates of major and minor bleeding. The incidence of even lesser degrees of
'nuisance' bleeding on DAPT and its impact on quality of life (QOL) are largely
unknown.
Methods: We studied 9290 ACS patients from the TRANSLATE ACS study who
were treated with PCI and discharged alive between April 2010 to Sept 2012.
Bleeding post-hospital discharge was deﬁned via the BARC bleeding deﬁnitions. Our
primary outcome was the 6 month EQ-5D index score, based on the U.S. population
preference weights. The EQ5D visual analog scale (VAS) at 6 months was
a secondary outcome. To determine the association between nuisance bleeding and 6-
month QOL, we ﬁt a mixed-effects linear regression model for 6 month EQ5D index
adjusting for baseline EQ5D index, with site as random effect (hierarchical model) and
other confounders of the relationship between bleeding and health status. We ﬁt
a similar model for EQ5D visual analog scale (VAS).
Results: Of the 9,290 patients with ACS (mean age 61, 73% males, 89% Whites),
4134 (44.5%) underwent immediate PCI for STEMI, and 4308 (46.4%) underwent
PCI for non-STEMI. A total of 849 (9.1%) patients experienced BARC I type
nuisance bleeding. Those who experienced BARC I bleeding had lower scores on all 5
EQ5D domains (mobility, self-care, usual activities, pain and anxiety) and had a lower
5 point EQ5D VAS score. After adjustment for confounders, nuisance bleeding by 6
month was independently associated with a decrement in QOL at 6 month (-2.04JACC Vol 62/18/Suppl B j October 27–November 1, 2013 j TCT Abstrpoints on EQ5D VAS; 95% CI -0.93 to -3.15, P<0.001). Based on the EQ5D index
score, the utility decrement associated with nuisance bleeding was 0.026, 95% CI
0.015 to 0.037, P-value <0.001.
Conclusions: In TRANSLATE-ACS, we found that BARC Type I (nuisance)
bleeding occurred in 1 of 10 patients after an ACS event and was associated with
worse 6-month quality of life and utility. These ﬁndings suggest that even nuisance
bleeds are relevant to patients and deserve greater attention in clinical recommenda-
tions for treatment and future clinical trials of prolonged DAPT therapies.
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Background: Platelet surface P-selectin and activated GPIIb-IIIa are markers of
platelet activation, degranulation and aggregation. In the TRITON trial prasugrel
(Pras) 10 mg reduced ischemic events vs. clopidogrel (Clop) 75 mg but increased
bleeding, notably in very elderly (VE) patients. Pras 5 mg is a treatment option in VE
patients but data on its effect on GPIIb-IIIa and P-selectin expression is lacking. We
performed a blinded, three-period cross-over study in stable CAD patients 75 y (VE)
or 45-65 y (NE) examining expression of these biomarkers following Pras (5 or 10
mg) and Clop 75 mg.
Methods: After a run-in on low dose aspirin, VE subjects (n¼23, 78  5 y) and NE
subjects (n¼22, 55  5 y) were randomized to Pras (5 or 10 mg) or Clop 75 mg during
three 12-day periods. ADP (20 mM)-stimulated platelet P-selectin and GPIIb-IIIa
(PAC-1) were measured by ﬂow-cytometry at baseline and at the end of each12-day
dosing period.
Results: PAC-1 and P-selectin (data not shown) expression after stimulation with 20
mM ADP did not differ between VE and NE at baseline or after any treatment period
(Figure). PAC-1 expression was signiﬁcantly reduced by pras 5 mg in both VE
(p<0.01) and NE (p<0.05). In the VE the 5 mg dose had similar effect as pras 10 mg.
Clop 75 mg did not signiﬁcantly reduce PAC-1 in VE. P-selectin expression showed
a similar proﬁle (data not shown).Conclusions: As assessed by GPIIb-IIIa and P-selectin in stable CAD patients, Pras 5
mg signiﬁcantly reduced ADP-induced platelet activation in the VE.
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Background: Increasingly cardiologists need to place coronary artery disease patients
implanted with drug-eluting stents on dual antiplatelet therapy (DAPT) regimens of
durations shorter than the 6-12 months recommended in current guidelines. Unfor-
tunately, no sufﬁcient clinical data are available to support such shorter DAPT
durations.
Methods: This prospective, nonrandomized, multicenter, controlled study of the
Endeavor zotarolimus-eluting stent (E-ZES) in real world Japanese patients consists of
two arms: patients who were enrolled at 106 medical institutions to receive DAPT for
3 months and then followed for 1year, and a 12-month DAPT arm consisting of
patients consecutively extracted from patients enrolled in the Endeavor Japan post-
marketing surveillance. The analysis was done on an intent to treat basis. Theacts/POSTER/Antiplatelets and Antithrombins B45
